| 32.54 4.52 (16.13%) | 07-09 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 38.54  |
1-year : | 45.01 |
| Resists | First : | 33 |
Second : | 38.54 |
| Pivot price | 23.97 |
|||
| Supports | First : | 19.26 |
Second : | 10.77 |
| MAs | MA(5) : | 26.81 |
MA(20) : | 21.16 |
| MA(100) : | 25.18 |
MA(250) : | 15.58 |
|
| MACD | MACD : | 2.5 |
Signal : | 1.4 |
| %K %D | K(14,3) : | 90.9 |
D(3) : | 82.9 |
| RSI | RSI(14): 74.4 |
|||
| 52-week | High : | 36.75 | Low : | 6.32 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ FTH ] has closed Bollinger Bands are 5.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 33 - 33.12 | 33.12 - 33.22 |
| Low: | 27.63 - 27.76 | 27.76 - 27.88 |
| Close: | 32.31 - 32.51 | 32.51 - 32.7 |
Faeth Therapeutics, Inc. is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. [28, 70] The company's lead program, PIKTOR, is an investigational all-oral combination therapy targeting the PI3K/AKT/mTOR pathway.
Fri, 03 Jul 2026
Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Wed, 01 Jul 2026
Faeth Therapeutics (FTH) CFO adds 13,634 shares via trust purchases - Stock Titan
Wed, 01 Jul 2026
FTH SEC Filings - Faeth Therapeutics, Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Mon, 29 Jun 2026
FTH - Faeth Therapeutics Inc Latest SEC Filings - Finviz
Sun, 28 Jun 2026
Faeth Therapeutics, Inc.(NasdaqCM: FTH) added to Russell 3000E Index - marketscreener.com
Thu, 25 Jun 2026
FTH | Faeth Therapeutics, Inc. Common Institutional Ownership - Quiver Quantitative
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 26 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 1.4 (%) |
| Held by Institutions | 25.6 (%) |
| Shares Short | 798 (K) |
| Shares Short P.Month | 834 (K) |
| EPS | -142.73 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -102.44 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -95.3 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -7.2 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -24 (M) |
| Levered Free Cash Flow | -92 (M) |
| PE Ratio | -0.23 |
| PEG Ratio | 0 |
| Price to Book value | -0.32 |
| Price to Sales | 0 |
| Price to Cash Flow | -34.83 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|